Core Viewpoint - CloudTop New Drug Company (1952.HK) has received approval for its core product, Arginine Ecurimod Tablets (brand name: Weishiping), for the treatment of moderate to severe active ulcerative colitis (UC) in adults who have inadequate response, loss of response, or intolerance to conventional therapies or biologics [1] Group 1: Product Approval and Market Potential - The product is a next-generation high-selectivity S1P receptor modulator, taken once daily, and is expected to provide a new first-line treatment option for adult UC patients [1] - The incidence of ulcerative colitis in China has been rising, with a projected increase in patient numbers from approximately 980,000 in 2025 to about 1.5 million by 2031 [1] - Sales peak for Arginine Ecurimod Tablets is predicted to reach 5 billion, positioning it as a core product for CloudTop following the success of its nephrology product, Renfu Kang [1] Group 2: Commercialization and Accessibility - The CEO of CloudTop, Luo Yongqing, stated that the company will accelerate the commercialization process of Weishiping and actively promote its inclusion in the national medical insurance catalog [1] - The focus is on enhancing the accessibility and affordability of innovative therapies in China [1]